One-year retention of gait speed improvement in stroke survivors after treatment with a wearable home-use gait device.
| Autor: | Darcy B; Moterum Technologies, Inc., Salt Lake City, UT, United States., Rashford L; Moterum Technologies, Inc., Salt Lake City, UT, United States., Tsai NT; Moterum Technologies, Inc., Salt Lake City, UT, United States., Huizenga D; Moterum Technologies, Inc., Salt Lake City, UT, United States., Reed KB; Department of Mechanical Engineering, University of South Florida, Tampa, FL, United States., Bamberg SJM; Moterum Technologies, Inc., Salt Lake City, UT, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in neurology [Front Neurol] 2024 Jan 11; Vol. 14, pp. 1089083. Date of Electronic Publication: 2024 Jan 11 (Print Publication: 2023). |
| DOI: | 10.3389/fneur.2023.1089083 |
| Abstrakt: | Background: Gait impairments after stroke are associated with numerous physical and psychological consequences. Treatment with the iStride ® gait device has been shown to facilitate improvements to gait function, including gait speed, for chronic stroke survivors with hemiparesis. This study examines the long-term gait speed changes up to 12 months after treatment with the gait device. Methods: Eighteen individuals at least one-year post-stroke completed a target of 12, 30-minute treatment sessions with the gait device in their home environment. Gait speed was measured at baseline and five follow-up sessions after the treatment period: one week, one month, three months, six months, and 12 months. Gait speed changes were analyzed using repeated-measures ANOVA from baseline to each follow-up time frame. Additional analysis included comparison to the minimal clinically important difference (MCID), evaluation of gait speed classification changes, and review of subjective questionnaires. Results: Participants retained an average gait speed improvement >0.21 m/s compared to baseline at all post-treatment time frames. Additionally, 94% of participants improved their gait speed beyond the MCID during one or more post-treatment measurements, and 88% subjectively reported a gait speed improvement. Conclusion: Treatment with the gait device may result in meaningful, long-term gait speed improvement for chronic stroke survivors with hemiparetic gait impairments. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03649217, identifier NCT03649217. Competing Interests: KR has a patent (US 9,295,302) related to this work. A management plan has been implemented and followed to reduce any effects of these conflicts of interest. The gait device is related to a commercial product by Moterum Technologies, Inc. BD, LR, DH, and SB receive a salary from Moterum Technologies. BD, LR, NT, DH, KR, and SB have stock options in Moterum Technologies, Inc. (Copyright © 2024 Darcy, Rashford, Tsai, Huizenga, Reed and Bamberg.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|